Advertisement

Topics

Phase I Study of Oral PQR309 in Patients With Relapsed or Refractory Lymphomas

2014-10-05 17:25:15 | BioPortfolio

Published on BioPortfolio: 2014-10-05T17:25:15-0400

Clinical Trials [2001 Associated Clinical Trials listed on BioPortfolio]

PQR309 in Patients With Relapsed or Refractory Primary CNS Lymphoma

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory PCNSL.

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nerv...

A Study of HMPL-523 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas or Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory B-cell Non-Hodgkin's Lymphomas or Chronic Lymphocytic ...

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in patients with relapsed or refractory lymphomas.

Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase) and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at pha...

PubMed Articles [1137 Associated PubMed Articles listed on BioPortfolio]

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high risk diffuse large B-cell lymphoma.

Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of sal...

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.

T-cell lymphoma is a rare hematologic malignancy with an incidence rate between 10% and 20% of that of non-Hodgkin lymphomas. Patients with peripheral T-cell lymphoma (PTCL) generally have a poor prog...

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an ...

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next-generation hypomethylating agent, could be useful in treating such patients.

Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study.

To evaluate the efficacy and safety of elotuzumab and dexamethasone (Ed) for relapsed or refractory multiple myeloma (RRMM) patients.

Medical and Biotech [MESH] Definitions

Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.

External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.

A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

A delayed response interval occurring when two stimuli are presented in close succession.

More From BioPortfolio on "Phase I Study of Oral PQR309 in Patients With Relapsed or Refractory Lymphomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial